Patent Grant
10751287
The present invention relates to the field of pharmaceutical dosage forms that are resistant to tampering, abuse and/or alcohol dose dumping.
Pharmaceutical products are sometimes the subject of abuse. For example, a particular dose of opioid agonist may be more potent when administered parenterally as compared to the same dose administered orally. Some formulations can be tampered with to provide the opioid agonist contained therein for illicit use. Opioid agonist formulations intended for oral use are sometimes crushed or subject to extraction with solvents (e.g., ethanol) by drug abusers to provide the opioid contained therein for non-prescribed illicit use (e.g., nasal or parenteral administration).
Controlled release oral dosage forms are sought out by abusers as the crushing of the dosage form may liberate an amount of active agent otherwise intended for prolonged release (e.g., 12 to 24 hours), making it immediately available. The immediate availability upon crushing may also make controlled release dosage forms more dangerous due to the possibility of accidental overdose.
There have previously been attempts in the art to control the abuse potential associated with opioid analgesics. For example, the combination of pentazocine and naloxone has been utilized in tablets available in the United States, commercially available as Talwin® Nx from Sanofi-Winthrop. Talwin® Nx contains pentazocine hydrochloride equivalent to 50 mg base and naloxone hydrochloride equivalent to 0.5 mg base. Talwin® Nx is indicated for the relief of moderate to severe pain. The amount of naloxone present in this combination has low activity when taken orally, and minimally interferes with the pharmacologic action of pentazocine. However, this amount of naloxone given parenterally has profound antagonistic action to narcotic analgesics. Thus, the inclusion of naloxone is intended to curb a form of misuse of oral pentazocine which occurs when the dosage form is solubilized and injected. Therefore, this dosage has lower potential for parenteral misuse than previous oral pentazocine formulations. A fixed combination therapy comprising tilidine (50 mg) and naloxone (4 mg) has been available in Germany for the management of severe pain since 1978 (Valoron® N, Goedecke). The rationale for the combination of these drugs is effective pain relief and the prevention of tilidine addiction through naloxone-induced antagonisms at the morphine receptor. A fixed combination of buprenorphine and naloxone was introduced in 1991 in New Zealand (Temgesic® Nx, Reckitt & Colman) for the treatment of pain.
Commonly owned U.S. Patent Application Publication No. 20090081290 is directed to opioid formulations that are resistant to crushing in attempts to liberate the drug contained therein for illicit use.
Commonly owned U.S. Patent Application Publication No. 20030068375 is directed to opioid formulations that in certain embodiments include a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid.
There exists a need in the art for a controlled release dosage form containing a drug susceptible to abuse that is resistant to providing an immediate release of the drug upon tampering. In the case of opioid analgesics, there exists a need for a tamper resistant formulation that does not solely rely upon the inclusion of an antagonist in the formulation to deter abuse.
All references described herein are hereby incorporated by reference in their entireties for all purposes.
It is an object of certain embodiments of the present invention to provide a solid oral dosage form comprising a drug susceptible to abuse (e.g., an opioid analgesic), which is tamper-resistant.
It is an object of certain embodiments of the present invention to provide a solid oral dosage form comprising a drug susceptible to abuse (e.g., an opioid analgesic), which is subject to less oral abuse than other dosage forms.
It is an object of certain embodiments of the present invention to provide a solid oral dosage form comprising a drug susceptible to abuse (e.g., an opioid analgesic), which is subject to less parenteral abuse than other dosage forms.
It is an object of certain embodiments of the present invention to provide a solid oral dosage form comprising a drug susceptible to abuse (e.g., an opioid analgesic), which is subject to less intranasal abuse than other dosage forms.
It is a further object of certain embodiments of the present invention to provide a solid oral dosage form comprising a drug susceptible to abuse (e.g., an opioid analgesic), which is subject to less diversion than other dosage forms.
It is a further object of certain embodiments of the present invention to provide a method of treating pain in human patients with a solid oral dosage form comprising an opioid analgesic while reducing the abuse potential of the dosage form.
It is a further object of certain embodiments of the present invention to provide a solid oral dosage form comprising a drug susceptible to abuse (e.g., an opioid analgesic), which is resistant to dose dumping in the presence of alcohol.
It is another object of certain embodiments of the present invention to treat a disease or condition (e.g., pain) by administering a solid oral dosage form as disclosed herein to a patient in need thereof.
It is another object of certain embodiments of the present invention to provide a method of manufacturing an oral dosage form of a drug susceptible to abuse (e.g., an opioid analgesic) as disclosed herein.
It is another object of certain embodiments of the present invention to provide a use of a medicament (e.g., an opioid analgesic) in the manufacture of a tamper-resistant dosage form as disclosed herein for the treatment of a disease state (e.g., pain).
In other embodiments, the invention is directed to a method of preparing the solid oral dosage forms disclosed herein, e.g., in tablet or capsule form.
In further embodiments, the present invention is directed to a method of treating a disease or condition (e.g., pain, diarrhea or constipation) comprising administering to a patient in need thereof an oral dosage form as disclosed herein.
One or more of the above objects, and others can be achieved by the present invention which in certain embodiments is directed to a solid oral dosage form comprising a plurality of particles, each particle comprising a core comprising an active agent susceptible to abuse and an internal adhesion promoter, wherein the cores are dispersed in a matrix comprising a controlled release material. In other embodiments, the solid oral dosage form comprises a plurality of particles, each particle comprising (i) a core comprising an active agent susceptible to abuse and an internal adhesion promoter and (ii) a controlled release coating comprising a controlled release material layered on the core. In each embodiment, the internal adhesion promoter promotes the adhesion of the active agent and the controlled release material.
In certain embodiments, the present invention is directed to a solid oral dosage form comprising a plurality of particles, each particle comprising a core comprising an active agent susceptible to abuse, a dissolution enhancer and an internal adhesion promoter, wherein the cores are dispersed in a matrix comprising a controlled release material. In other embodiments, the solid oral dosage form comprises a plurality of particles, each particle comprising (i) a core comprising an active agent susceptible to abuse, a dissolution enhancer and an internal adhesion promoter and (ii) a controlled release coating comprising a controlled release material layered on the core.
In certain embodiments, the present invention is directed to a solid oral dosage form comprising a plurality of particles, each particle comprising a core comprising an active agent susceptible to abuse and an internal adhesion promoter, wherein the cores are dispersed in a matrix comprising a controlled release material and a pore former. In other embodiments, the solid oral dosage form comprises a plurality of particles, each particle comprising (i) a core comprising an active agent susceptible to abuse, an internal adhesion promoter and a dissolution enhancer and (ii) a controlled release coating comprising a controlled release material and a pore former, layered on the core.
In certain embodiments, the present invention is directed to a solid oral dosage form comprising a plurality of particles, each particle comprising a core comprising an active agent susceptible to abuse, a dissolution enhancer and an internal adhesion promoter, wherein the cores are dispersed in a matrix comprising a controlled release material and an alcohol resistant material. In one embodiment, the cores can first be dispersed in the controlled release material (and optional pore former) with the resultant dispersion further dispersed in the alcohol resistant material or vice versa. In another embodiment, the cores can be dispersed simultaneously with both the controlled release material and the alcohol resistant material. In other embodiments, the solid oral dosage form comprises a plurality of particles, each particle comprising (i) a core comprising an active agent susceptible to abuse, an internal adhesion promoter and a dissolution enhancer, (ii) a controlled release coating comprising a controlled release material and a pore former, layered on the core and (iii) an alcohol resistant coating comprising an alcohol resistant material layered over the controlled release coating.
In certain embodiments, the present invention is directed to a solid oral dosage form comprising a plurality of particles, each particle comprising a core comprising an active agent susceptible to abuse, a dissolution enhancer and an internal adhesion promoter, wherein the core is dispersed in a matrix comprising a controlled release material, an alcohol resistant material and an external adhesion promoter. In one embodiment, the cores can first be dispersed in the controlled release material (and optional pore former) with the resultant dispersion further dispersed in the alcohol resistant material and external adhesion promoter (or vice versa). In another embodiment, the cores can be dispersed simultaneously with the controlled release material and the alcohol resistant material (and the optional external adhesion promoter). In other embodiments, the solid oral dosage form comprises a plurality of particles, each particle comprising (i) a core comprising an active agent susceptible to abuse, an internal adhesion promoter and a dissolution enhancer, (ii) a controlled release coating comprising a controlled release material and a pore former, layered on the core and (iii) an alcohol resistant coating comprising an alcohol resistant material and an external adhesion promoter layered over the controlled release coating.
In certain embodiments, the present invention is directed to a solid oral dosage form comprising a plurality of particles, each particle comprising a core comprising an opioid agonist and a carbomer, wherein the core is dispersed in a matrix comprising a neutral acrylic polymer, a pore former, an alkylcellulose and a carbomer. In one embodiment, the cores can first be dispersed in the neutral acrylic polymer (and optional pore former) with the resultant dispersion further dispersed in the allylcellulose (and optional carbomer) (or vice versa). In another embodiment, the cores can be dispersed simultaneously with the neutral acrylic polymer and the alkylcellulose. In other embodiments, the solid oral dosage form comprises a plurality of particles, each particle comprising (i) a core comprising an opioid agonist and a carbomer; (ii) a controlled release coating comprising a neutral acrylic polymer and a pore former; and (iii) an alcohol resistant coating comprising an alkylcellulose and a carbomer.
In certain embodiments, the present invention is directed to a process for preparing a solid oral dosage form comprising preparing a plurality of particles by (i) granulating an opioid agonist and a carbomer to form core granules; (ii) mixing, granulating or coating the core granules with a neutral acrylic polymer and lactose to obtain controlled release particles (e.g., granules; (iii) mixing, granulating or coating the controlled release particles with methylcellulose and a carbomer to obtain alcohol resistant controlled release particles (e.g., granules); and (iv) compressing the alcohol resistant controlled release particles into a tablet or containing the particles in a capsule.
In certain embodiments, the solid oral dosage forms disclosed herein provide a controlled release of the active agent contained therein such that the dosage form is suitable for administration on a once daily (Q.D.) or twice daily (B.I.D.) basis.
In describing the present invention, the following terms are to be used as indicated below. As used herein, the singular forms “a,” “an,” and “the” include plural references unless the context clearly indicates otherwise. Thus, for example, reference to “a drug susceptible to abuse” includes a single active agent as well as a mixture of two or more different active agents, and reference to a “gelling agent” includes a single gelling agent as well as a mixture of two or more different gelling agents, and the like.
As used herein, the terms “active agent,” “active ingredient,” “pharmaceutical agent,” and “drug” refer to any material that is intended to produce a therapeutic, prophylactic, or other intended effect, whether or not approved by a government agency for that purpose. These terms with respect to specific agents include all pharmaceutically active agents, all pharmaceutically acceptable salts thereof, and all complexes, stereoisomers, crystalline forms, amorphous form, cocrystals, ether, esters, hydrates and solvates thereof, and mixtures thereof, which produce the intended effect.
As used herein, the terms “therapeutically effective” refers to the amount of drug or the rate of drug administration needed to produce a desired therapeutic result.
As used herein, the terms “prophylactically effective” refers to the amount of drug or the rate of drug administration needed to produce a desired prophylactic result.
As used herein, the term “stereoisomers” is a general term for all isomers of individual molecules that differ only in the orientation of their atoms in space. It includes enantiomers and isomers of compounds with one or more chiral centers that are not mirror images of one another (diastereomers).
The term “enantiomer” or “enantiomeric” refers to a molecule that is nonsuperimposable on its mirror image and hence optically active wherein the enantiomer rotates the plane of polarized light in one direction by a certain degree, and its mirror image rotates the plane of polarized light by the same degree but in the opposite direction.
The term “chiral center” refers to a carbon atom to which four different groups are attached.
The term “patient” means a subject who has presented a clinical manifestation of a particular symptom or symptoms suggesting the need for treatment, who is treated preventatively or prophylactically for a condition, or who has been diagnosed with a condition to be treated.
“Pharmaceutically acceptable salts” include, but are not limited to, inorganic acid salts such as hydrochloride, hydrobromide, sulfate, phosphate and the like; organic acid salts such as formate, acetate, trifluoroacetate, maleate, tartrate and the like; sulfonates such as methanesulfonate, benzenesulfonate, p-toluenesulfonate and the like; amino acid salts such as arginate, asparaginate, glutamate and the like; metal salts such as sodium salt, potassium salt, cesium salt and the like; alkaline earth metals such as calcium salt, magnesium salt and the like; and organic amine salts such as triethylamine salt, pyridine salt, picoline salt, ethanolamine salt, triethanolamine salt, discyclohexylamine salt, N,N′-dibenzylethylenediamine salt and the like.
The term “subject” is inclusive of the definition of the term “patient” and does not exclude individuals who are entirely normal in all respects or with respect to a particular condition.
The term “ppm” as used herein means “parts per million”. Regarding 14-hydroxycodeinone, “ppm” means parts per million of 14-hydroxycodeinone in a particular sample product. The 14-hydroxycodeinone level can be determined by any method known in the art, preferably by HPLC analysis using UV detection.
The term “recovery” means the amount of drug obtained from the resultant solution of a tampered dosage form (e.g., crushing and mixing in 5 mL solvent) upon aspiration with a 27 gauge needle.
The term “tampering” means a manipulation by mechanical, thermal, and/or chemical means to obtain a solution of drug available for illicit use. The tampering can be, e.g., by means of crushing and mixing then dosage form with a solvent (with or without heat), or by dissolution of an intact dosage form in a solvent (with or without heat).
The term “adhesion promoter” means a compound that maintains an interaction (e.g., chemical or physical) between two other compounds to maintain a desired characteristic of the interacted compounds. For example, an adhesion promoter of the present invention (e.g., carbomer, either internally or externally) maintains the interaction between the active agent and the controlled release material such that a controlled release of the active agent is maintained, even when the dosage form is crushed in an attempt to liberate the active agent for an immediate release. In another example, an adhesion promoter of the present invention (e.g., carbomer either internally or externally) maintains the interaction between the controlled release material and the alcohol resistant material such that the dosage form does not dose dump in the presence of alcohol.
The term “internal adhesion promoter” means a compound that is an adhesion promoter and is contained in the core of the dosage forms disclosed herein.
The term “external adhesion promoter” means a compound that is an adhesion promoter and is contained outside the core of the dosage forms disclosed herein
Controlled release dosage forms play a vital part in the management of both acute and chronic conditions (e.g., pain management with opioid analgesics). Therefore, it is important to provide a tamper-resistant controlled release dosage form of a drug susceptible to abuse that may be utilized to provide effective plasma levels to a patient according to an intended release profile, while not being susceptible to significant dose dumping when the dosage form is crushed in an attempt to liberate the active agent contained therein for illicit use.
In certain embodiments, the dosage forms contained herein provide an in-vitro dissolution of the active agent contained therein indicative of a controlled release profile such that it can be administered on a once daily or twice daily basis. By virtue of the present invention, when the dosage form is crushed according to the methods disclosed herein, the in-vitro dissolution profile is maintained, decreased or not significantly increased (e.g., by no more than a 30% increase at 1 hour), such that the administration of a crushed dosage form would not likely provide any more of a euphoric effect than the administration of an intact dosage form.
In certain embodiments, the dosage forms contained herein provide an in-vitro dissolution of the active agent contained therein indicative of a controlled release profile and when the dosage form is subject to dissolution in an alcohol containing solvent (e.g., SGF with 40% EtOH) according to the methods disclosed herein, the in-vitro dissolution profile is maintained, decreased or not significantly increased (e.g., by no more than a 20% increase at 1 hour), such that the administration of dosage form with alcohol would not dose dump and would not likely provide any more of a euphoric effect than the administration of an intact dosage form. This attribute would also deter the tampering of the dosage form by dissolution in an alcohol containing solvent in an attempt to liberate the active agent contained therein for illicit use.
In certain embodiment, the present invention is directed to a solid oral dosage form comprising a plurality of particles, each particle comprising a core comprising an active agent susceptible to abuse and an internal adhesion promoter, wherein the cores are dispersed in a matrix comprising a controlled release material. In other embodiments, the solid oral dosage form comprises a plurality of particles, each particle comprising (i) a core comprising an active agent susceptible to abuse (e.g., an opioid agonist) and (ii) a controlled release coating comprising a controlled release material layered on the core. The core may further comprise an internal or external adhesion promoter to promote the adhesion of the active agent and the controlled release material such that a controlled release profile is provided when the dosage form is administered intact and/or the dissolution profile is not significantly changed when the dosage form is tampered with in an attempt to liberate the active agent contained thereof or illicit use.
The core of the particles can also contain a dissolution enhancer to balance the controlled release provided by the controlled release material, such that enough active agent is released from the dosage form to provide a desired release profile and pharmacodynamic response.
In addition to, or in place of the dissolution enhancer in the dosage form, the controlled release coating of the particles may include a pore former, that also may act to enhance the release of the active agent contained therein such that enough active agent is released from the dosage form to provide a desired release profile and pharmacodynamic response.
In embodiments that are resistant to dissolution in alcohol containing solvents, such resistance can be provided by an alcohol resistant material mixed or granulated with, or coated over the controlled release material. The alcohol resistant material may further comprise an external adhesion promoter to promote the adhesion of the alcohol resistant material and the controlled release material in order to obtain, enhance or maintain the alcohol resistance characteristics of the dosage form.
In certain embodiments, the controlled release material is a polymer that can modify the release rate of the active agent contained therein. Examples of polymers that can be utilized to modify the release of the active agent include pharmaceutically acceptable cellulosic polymers, including but not limited to alkyl celluloses, cellulose esters, cellulose diesters, cellulose triesters, cellulose ethers, cellulose ester-ethers, cellulose acylates, cellulose diacylates, cellulose triacylates, cellulose acetates, cellulose diacetates, cellulose triacetates, cellulose acetate propionates, cellulose acetate butyrates and mixtures thereof.
In other embodiments of the present invention, the controlled release polymer is a pharmaceutically acceptable acrylic polymer selected without limitation from acrylic acid and methacrylic acid copolymers, methyl methacrylate copolymers, ethoxyethyl methacrylates, cyanoethyl methacrylate, aminoalkyl methacrylate copolymer, poly(acrylic acid), poly(methacrylic acid), methacrylic acid alkylamide copolymer, poly(methyl methacrylate), poly(methacrylic acid) (anhydride), methyl methacrylate, polymethacrylate, poly(methyl methacrylate), poly(methyl methacrylate) copolymer, polyacrylamide, aminoalkyl methacrylate copolymer, poly(methacrylic acid anhydride), glycidyl methacrylate copolymers, and mixtures of any of the foregoing. Preferably, the acrylic polymer is a neutral acrylic polymer (e.g., Eudragit NE 30 D®, Eudragit NE 40 D® or Eudragit NM 30 D®), which can also provide crush-resistant characteristics to the individual particles. However, when the particles are crush resistant and compressed into a tablet, the tablet breaks apart wherein the tablet is subject to a typical force used in tampering. In certain embodiments, the tablet has a breaking strength of less than about 400N, less than about 350N, less than about 300N or less than about 250N.
The internal adhesion promoter may be selected from the group consisting of a cellulosic material, a surfactant, a carbomer and a mixture thereof. In certain embodiments, the cellulosic material used as an internal adhesion promoter is hydroxypropylmethylcellulose. In certain embodiments, the surfactant used as an internal adhesion promoter is a non-ionic surfactant such as a nonoxynol (e.g., nonoxynol-9) or a sorbitan ester (e.g., Span 20®) and a mixture thereof.
In a particular embodiment, the internal adhesion promoter is an anionic polymer such as a polyacrylic acid. The polyacrylic acid can be a homopolymer and can be optionally crosslinked with a crosslinking agent (referred to as a carbomer). The cross-linking agent can be a polyalcohol allyl ether such as an allyl ether pentaerythritol, an allyl ether of sucrose, an allyl ether of propylene or a mixture thereof.
The dissolution enhancer, when utilized in the present invention, can be a pharmaceutically acceptable cellulosic polymer, including but not limited to alkyl celluloses, cellulose esters, cellulose diesters, cellulose triesters, cellulose ethers, cellulose ester-ethers, cellulose acylates, cellulose diacylates, cellulose triacylates, cellulose acetates, cellulose diacetates, cellulose triacetates, cellulose acetate propionates, cellulose acetate butyrates and mixtures thereof. In a particular embodiment, the dissolution enhancer is methylcellulose.
The pore former, when utilized in the present invention, can be a water soluble material that enhances release by creating channels or passageways in the controlled release coating, or by otherwise weakening the integrity of the coating upon exposure to an environmental fluid. The pore former can be a polysaccharide such as lactose, dextrose, mannitol or mixture thereof, a cellulosic material such as microcrystalline cellulose, hydroxypropylmethylcellulose or a mixture thereof, or a material such as polyvinyl alcohol.
The alcohol resistant material utilized in the present invention can be any pharmaceutically acceptable material that is capable of providing resistance to dissolution in an alcohol containing solvent. The alcohol resistant material may be an alkylcellulose such as methylcellulose.
The external adhesion promoter may be selected from the group consisting of a cellulosic material, a surfactant, a carbomer and a mixture thereof. The external adhesion promoter can be the same or different than the internal adhesion promoter. In certain embodiments, the cellulosic material used as an external adhesion promoter is hydroxypropylmethylcellulose. In certain embodiments, the surfactant used as an external adhesion promoter is a non-ionic surfactant such as a nonoxynol (e.g., nonoxynol-9) or a sorbitan ester (e.g., Span 20®) and a mixture thereof.
In a particular embodiment, the external adhesion promoter is an anionic polymer such as a polyacrylic acid. The polyacrylic acid can be a homopolymer and can be optionally crosslinked with a crosslinking agent (a carbomer). The cross-linking agent can be a polyalcohol allyl ether such as an allyl ether pentaerythritol, an allyl ether of sucrose, an allyl ether of propylene or a mixture thereof.
A unit dose of a plurality of particles of the present invention can be administered in any suitable form, e.g., in a capsule (e.g., a gelatin capsule), contained in a powder paper, or compressed into a tablet.
The dosage forms of the present invention can be prepared by mixing the active agent and the adhesion promoter together to form a plurality of cores. The cores can be prepared by granulating the materials to form core granules, by compression of a mixture of the components, or by layering the components over an inert substance such as non-pareil beads.
The core granules can then be mixed, granulated or coated with the controlled release material and the optional pore former to obtain controlled release particles. This process may include spray coating the core particles (e.g., core granules) with the controlled release material and optional pore former or by granulating the core particles with the controlled release material and optional pore former.
The controlled release particles can then be mixed, granulated or coated with alcohol resistant material to obtain alcohol resistant controlled release particles. This process may include spray coating the controlled release particles (e.g., controlled release granules) with the alcohol resistant material and optional external adhesion promoter or by granulating the controlled release particles with the alcohol resistant material and optional external adhesion promoter.
The alcohol resistant controlled release particles can then be contained within a pharmaceutically acceptable capsule or compressed into a tablet.
In certain embodiments, the weight ratio of the active agent to the controlled release material is from about 2:1 to about 1:100; from about 1:5 to about 1:50; from about 1:1 to about 1:75 or from about 1:10 to about 1:30.
In certain embodiments, the particles can have a mean diameter from about 0.1 mm to about 2 mm; from about 0.2 mm to about 1 mm; or from about 0.3 mm to about 0.8 mm.
In certain embodiments, the solid oral dosage form of the present invention comprises from about 0.1% to about 80% (w/w) active agent; from about 0.5% to about 60% (w/w) active agent; from about 1% to about 40% (w/w) active agent; from about 0.1% to about 30% (w/w) active agent; from about 0.5% to about 20% (w/w) active agent; from about 1% to about 10% (w/w) active agent or from about 1% to about 5% active agent.
In certain embodiments, the solid oral dosage form of the present invention comprises from about 10% to about 90% (w/w) controlled release material; from about 25% to about 75% (w/w) controlled release material; or from about 40% to about 60% (w/w) controlled release material.
In certain embodiments, the solid oral dosage form of the present invention comprises from about 0.05% to about 10% (w/w) internal adhesion promoter; from about 0.1% to about 5 (w/w) internal adhesion promoter; or from about 0.5% to about 3% (w/w) internal adhesion promoter.
In certain embodiments, the solid oral dosage form of the present invention comprises from about 1% to about 40% (w/w) dissolution enhancer; from about 5% to about 30% (w/w) dissolution enhancer; or from about 10% to about 20% (w/w) dissolution enhancer.
In certain embodiments, the solid oral dosage form of the present invention comprises from about 0.5% to about 25% (w/w) pore former; from about 1% to about 15% (w/w) pore former; or from about 2% to about 10% (w/w) pore former.
In certain embodiments, the solid oral dosage form of the present invention comprises from about 1% to about 50% (w/w) alcohol resistant material; from about 5% to about 40% (w/w) alcohol resistant material; or from about 10% to about 30% (w/w) alcohol resistant material.
In certain embodiments, the solid oral dosage form of the present invention comprises from about 0.5% to about 15% (w/w) external adhesion promoter; from about 1% to about 10% (w/w) external adhesion promoter; or from about 2% to about 8% (w/w) external adhesion promoter.
In certain embodiments, the solid oral dosage form of the present invention provides a dissolution release rate in-vitro of the active agent, when measured by the USP Type 2, Paddle Method at 50 rpm in 900 ml Simulated Gastric Fluid (SGF) without enzymes at 37° C. of at least about 15% by weight of the active agent released at 1 hour, from about 25% to about 65% by weight of the active agent released at 2 hours, from about 45% to about 85% by weight of the active agent released at 4 hours, and at least about 60% by weight of the active agent released at 8 hours.
In certain embodiments, the solid oral dosage form of the present invention provides a dissolution release rate in-vitro of the active agent, when measured by the USP Type 2, Paddle Method at 50 rpm in 900 ml Simulated Gastric Fluid (SGF) without enzymes at 37° C. of at least about 20% by weight of the active agent released at 4 hours, from about 20% to about 65% by weight of the active agent released at 8 hours, from about 45% to about 85% by weight of the active agent released at 12 hours, and at least about 80% by weight of the active agent released at 24 hours.
In certain embodiments, the amount of active agent released from the dosage forms of the present invention at 0.5 hour, 1 hour, 2 hours and/or 4 hours when measured in a USP Type 2, Paddle Method at 50 rpm in 900 ml simulated gastric fluid (SGF) without enzymes with 40% ethanol at 37° C., is within 30% (higher or lower) of the amount of active agent released at the same time period when measured in a USP Type 2, Paddle Method at 50 rpmin 900 ml simulated gastric fluid without enzymes (SGF) with 0% ethanol at 37°.
In certain embodiments, the amount of active agent released from the dosage forms of the present invention at 0.5 hour, 1 hour, 2 hours and/or 4 hours when measured in a USP Type 2, Paddle Method at 50 rpm in 900 ml simulated gastric fluid (SGF) without enzymes with 40% ethanol at 37° C., is within 25% of the amount of active agent released at the same time period when measured in a USP Type 2, Paddle Method at 50 rpm in 900 ml simulated gastric fluid without enzymes (SGF) with 0% ethanol at 37°.
In certain embodiments, the amount of active agent released from the dosage forms of the present invention at 0.5 hour, 1 hour, 2 hours and/or 4 hours when measured in a USP Type 2, Paddle Method at 50 rpm in 900 ml simulated gastric fluid (SGF) without enzymes with 40% ethanol at 37° C., is within 20% of the amount of active agent released at the same time period when measured in a USP Type 2, Paddle Method at 50 rpm in 900 ml simulated gastric fluid without enzymes (SGF) with 0% ethanol at 37°.
In certain embodiments, the amount of active agent released from the dosage forms of the present invention at 0.5 hour, 1 hour, 2 hours and/or 4 hours when measured in a USP Type 2, Paddle Method at 50 rpm in 900 ml simulated gastric fluid (SGF) without enzymes with 40% ethanol at 37° C., is within 10% of the amount of active agent released at the same time period when measured in a USP Type 2, Paddle Method at 50 rpm in 900 ml simulated gastric fluid without enzymes (SGF) with 0% ethanol at 37°.
In certain embodiments, the amount of active agent released from the dosage forms of the present invention at 0.5 hour, 1 hour, 2 hours and/or 4 hours when measured in a USP Type 2, Paddle Method at 50 rpm in 900 ml simulated gastric fluid (SGF) without enzymes with 40% ethanol at 37° C., is within 5% of the amount of active agent released at the same time period when measured in a USP Type 2, Paddle Method at 50 rpm in 900 ml simulated gastric fluid without enzymes (SGF) with 0% ethanol at 37°.
In certain embodiments, the amount of active agent released at 0.5 hour, 1 hour, 2 hours or 4 hours when measured in a USP Type 2, Paddle Method at 50 rpm in 900 ml simulated gastric fluid (SGF) without enzymes with 40% ethanol at 37° C., is less than the amount of active agent released at the same time period when measured in a USP Type 2, Paddle Method at 50 rpm in 900 ml simulated gastric fluid without enzymes (SGF) with 0% ethanol at 37°.
In certain embodiments, the amount of active agent released from a crushed dosage form at 0.5 hour, 1 hour, 2 hours or 4 hours when measured in a USP Type 2, Paddle Method at 50 rpm in 900 ml simulated gastric fluid (SGF) without enzymes at 37° C., is within 30% of the amount of active agent released from an intact dosage form at the same time period when measured in a USP Type 2, Paddle Method at 50 rpm in 900 ml simulated gastric fluid without enzymes (SGF) with 0% ethanol at 37°.
In certain embodiments, the amount of active agent released from a crushed dosage form at 0.5 hour, 1 hour, 2 hours or 4 hours when measured in a USP Type 2, Paddle Method at 50 rpm in 900 ml simulated gastric fluid (SGF) without enzymes at 37° C., is within 25% of the amount of active agent released from an intact dosage form at the same time period when measured in a USP Type 2, Paddle Method at 50 rpm at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) with 0% ethanol at 37°.
In certain embodiments, the amount of active agent released from a crushed dosage form at 0.5 hour, 1 hour, 2 hours or 4 hours when measured in a USP Type 2, Paddle Method at 50 rpm in 900 ml simulated gastric fluid (SGF) without enzymes at 37° C., is within 20% of the amount of active agent released from an intact dosage form at the same time period when measured in a USP Type 2, Paddle Method at 50 rpm in 900 ml simulated gastric fluid without enzymes (SGF) with 0% ethanol at 37°.
In certain embodiments, the amount of active agent released from a crushed dosage form at 0.5 hour, 1 hour, 2 hours or 4 hours when measured in a USP Type 2, Paddle Method at 50 rpm in 900 ml simulated gastric fluid (SGF) without enzymes at 37° C., is within 15% of the amount of active agent released from an intact dosage form at the same time period when measured in a USP Type 2, Paddle Method at 50 rpm in 900 ml simulated gastric fluid without enzymes (SGF) with 0% ethanol at 37°.
In certain embodiments, the amount of active agent released from a crushed dosage form at 0.5 hour, 1 hour, 2 hours or 4 hours when measured in a USP Type 2, Paddle Method at 50 rpm in 900 ml simulated gastric fluid (SGF) without enzymes at 37° C., is within 10% of the amount of active agent released from an intact dosage form at the same time period when measured in a USP Type 2, Paddle Method at 50 rpmin 900 ml simulated gastric fluid without enzymes (SGF) with 0% ethanol at 37°.
In certain embodiments, the amount of active agent released from a crushed dosage form at 0.5 hour, 1 hour, 2 hours or 4 hours when measured in a USP Type 2, Paddle Method at 50 rpm in 900 ml simulated gastric fluid (SGF) without enzymes at 37° C., is within 5% of the amount of active agent released from an intact dosage form at the same time period when measured in a USP Type 2, Paddle Method at 50 rpm in 900 ml simulated gastric fluid without enzymes (SGF) with 0% ethanol at 37°.
The dosage forms of the present invention can include additional excipients in order to, e.g., aid manufacturing, provide additional tamper resistance, further modify the release rate, or further modify alcohol resistance.
Additional excipients may include at least one excipient selected from the group consisting of bulking agents or fillers, plasticizers, stabilizers, diluents, lubricants, disintegrants, binders, granulating aids, colorants, flavorants, and glidants.
The drug susceptible to abuse can be dry-blended with the internal adhesion promoter and any additional excipients prior to being formed into core particles. In certain embodiments, the materials can be wet-granulated, dried, and optionally milled to prepare the core particles.
In certain embodiments, the controlled release material can be included in the core particles, alternatively, or in addition to, the controlled release matrix or coating. The controlled release matrix or coating can include one or more controlled release materials and optional pore former and be mixed with, granulated with or layered over the core particles to achieve a weight gain, e.g., of from about 1% to about 500%, from about 25% to about 400%, or from about 50% to about 300% (w/w).
The dosage forms can also include a coating to enhance cosmetic appearance and/or to reduce tackiness. Examples of materials to be utilized as a film coat include hydroxypropylmethylcellulose, polyvinyl alcohol, lactose, and mixtures thereof. The film coat can be: (i) an outer coating directly coated onto a dosage form (e.g., a compressed tablet or an individual particle), or (ii) an intermediate coating between the core and the controlled release matrix or coating and/or the controlled release matrix or coating and the alcohol resistant matrix or coating.
In certain embodiments, the plurality of particles can be combined with additional excipients prior to being compressed into a tablet. Such additional excipients can be disintegrants, fillers, flow aids, lubricants and gelling agents. The gelling agent can be in an amount to be an aversive agent by forming a viscous solution upon introduction with a small amount of a solvent. The resultant viscosity would hinder the ability to have the active agent contained therein administered by the parenteral or nasal route.
The disintegrant can be an agent such as, e.g., polyvinylpyrrolidone, sodium starch glycolate, crosscarmellose sodium, or a mixture thereof. The filler or diluent can be an agent such as, e.g., lactose, dextrose, mannitol, microcrystalline cellulose, or a mixture thereof.
The gelling agent utilized in certain embodiments of the present invention can be selected from sugars, sugar derived alcohols (e.g., mannitol, sorbitol, and the like), starch and starch derivatives, cellulose derivatives (e.g., microcrystalline cellulose, sodium carboxymethyl cellulose, methylcellulose, ethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, and hydroxypropyl methylcellulose), attapulgites, bentonites, dextrins, alginates, carrageenan, gums (e.g., gum tragacanth, gum acacia, guar gum, and xanthan gum), pectin, gelatin, kaolin, lecithin, magnesium aluminum silicate, polyvinylpyrrolidone, polyethylene glycol, polyethylene oxide, polyvinyl alcohol, silicon dioxide, curdlan, furcelleran, egg white powder, lacto albumin, soy protein, chitosan, surfactants, mixed surfactant/wetting agent systems, emulsifiers, other polymeric materials, and mixtures thereof. In certain embodiments, the gelling agent is xanthan gum. In other embodiments, the gelling agent is pectin. The pectin or pectic substances include purified or isolated pectates and crude natural pectin from sources such as apple, citrus or sugar beet residues which have been subjected, when necessary, to esterification or de-esterification (e.g., by alkali or enzymes). The pectins may also be derived from citrus fruits such as lime, lemon, grapefruit, and orange. In particular embodiments, the gelling agent may be selected from the group consisting of pregelatinized starch (e.g., Swelstar® from Asahi Kasei), hydroxyethylcellulose (e.g., Natrosol® from Ashland Inc.), guar gum (e.g., Supercol® from Ashland Inc.), xanthan gum, alginate, carrageenan, polyethyelene oxide and a mixture thereof.
In addition to gelling agents, the dosage forms of the present invention can include other aversive agents to further deter the illicit use of the drug contained therein. These other aversive agents can be, e.g., an emetic, an antagonist, a bittering agent, an irritant, or a mixture thereof. They can be incorporated into the particles, or added separately within a capsule or as additional tableting excipients.
The emetic may be selected from, e.g., the group consisting of methyl cephaeline, cephaeline, emetine hydrochloride, psychotrine, O-methylpsychotrine, emetamine, ipecamine, hydro-ipecamine, ipecacunhic acid and mixtures thereof. In particular embodiments, the emetic is ipecac.
The antagonist may be selected from, e.g., the group consisting of naltrexone, naloxone, nalmefene, cyclazacine, levallorphan, pharmaceutically acceptable salts thereof, and mixtures thereof.
The bittering agent may be selected from, e.g., the group consisting of flavor oils, flavoring aromatics, oleoresins, plant extracts, leaf extracts, flower extracts, fruit extracts, sucrose derivatives, chlorosucrose derivatives, quinine sulphate, denatonium benzoate and mixtures thereof. In certain embodiments, the bittering agent is spearmint oil, peppermint oil, eucalyptus oil, oil of nutmeg, allspice, mace, oil of bitter almonds, menthol or a mixture thereof. In other embodiments, the bittering agent extracted from a fruit is selected from the group consisting of lemon, orange, lime, grapefruit, and mixtures thereof. In a particular embodiment, the bittering agent is denatonium benzoate.
The irritant may be selected from, e.g., a surfactant, capsaicin or a capsaicin analog. The capsaicin analog can be selected from the group consisting of resiniferatoxin, tinyatoxin, heptanoylisobutylamide, heptanoyl guaiacylamide, an isobutylamide, a guaiacylamide, dihydrocapsaicin, homovanillyl octylester, nonanoyl vanillylamide, and mixtures thereof.
The surfactant can be selected from the group consisting of poloxamer, a sorbitan monoester, a glyceryl monooleate, sodium lauryl sulfate and mixtures thereof.
The surfactant can be included in the dosage form in an amount, e.g., from about 1% to about 25% (w/w) of the dosage form; from about 4% to about 15% (w/w) of the dosage form; from about 2.5% to about 10% (w/w) of the dosage form or from about 8% to about 12% (w/w) of the dosage form.
In embodiments using gelling agents, the solid oral dosage forms of the present invention when mixed or crushed and mixed (with or without heat) with from about 0.5 to about 10 ml of distilled water, provides a viscosity that prevents or reduces the ability of the drug from being drawn up into a syringe, or systemically absorbed when parenteral or nasal administration is attempted.
In certain embodiments, the viscosity after tampering with from about 0.5 to about 10 ml of distilled water is at least about 10 cP, at least about 50 cP, at least about 100 cP, at least about 500 cP or at least about 1,000 cP.
In certain embodiments, the viscosity after tampering with from about 0.5 to about 10 ml of distilled water is from about 50 cP to about 100,000 cP; from about 75 cP to about 50,000 cP; from about 100 cP to about 25,000 cP; from about 150 cP to about 10,000 cP; from about 200 cP to about 5,000 cP; or from about 250 cP to about 1,000 cP.
In certain embodiments, the recovery of the drug is, e.g., less than about 50%, less than about 40%, less than about 30%, less than about 20%, less than about 10%, less than about 8%, less than about 6%, less than about 4%, less than about 2%, less than about 1%, less than about 0.8%, less than about 0.6%, less than about 0.4%, or less than less than about 0.2%, based on a syringability test whereby the dosage form is mixed or crushed and mixed with 5 mL solvent and the resultant solution is aspired with a 27 gauge needle.
The solvent utilized in the syringability test can be, e.g., tap water, distilled water, sterile saline, vinegar or 40% ethanol. Also, during the syringability test, the solvent (before or after mixing with the dosage form) can be subject to heat from any source such as, e.g., by the use of a butane lighter.
In certain embodiments of the present invention, the recovery of the drug is, e.g., less than about 10%, less than about 8%, less than about 6%, less than about 4%, less than about 2%, less than about 1%, less than about 0.8%, less than about 0.6%, less than about 0.4%, or less than less than about 0.2%, based on both heated and unheated syringability tests, whereby the dosage form is mixed or crushed and mixed with 5 mL solvent and the resultant solution is aspired with a 27 gauge needle.
In certain embodiments, the ratio of extraction from an unheated syringability test to a heated syringability test is from about 1:5 to about 5:1; from about 1:4 to about 4:1; from about 1:3 to about 3:1; from about 1:2 to about 2:1; from about 1:1.5 to about 1.5:1; from about 1:1.3 to about 1.3:1 or from about 1:1.1 to about 1.1:1.
In certain embodiments of the present invention, the recovery of the drug from small volume extraction at 10 minutes and/or 60 minutes is, e.g., less than about 90%, less than about 80%, less than about 70%, less than about 60%, less than about 50%, less than about 40%, less than about 30%, less than about 20%, less than about 10%, less than about 8%, less than about 6%, less than about 4%, less than about 2%, less than about 1%, less than about 0.8%, less than about 0.6%, less than about 0.4%, or less than less than about 0.2%, based on both heated and unheated extraction tests, whereby the dosage form is mixed or crushed and mixed with 30 mL of a solvent. The small volume extraction can be measured, e.g., by the procedures of Example 3.
In certain embodiments, the ratio of extraction from an unheated small volume extraction test at 10 minutes and/or 60 minutes to a corresponding heated extraction test is from about 1:50 to about 50:1; from about 1:40 to about 40:1; from about 1:30 to about 30:1; from about 1:20 to about 20:1; from about 1:10 to about 10:1; from about 1:5 to about 5:1; from about 1:4 to about 4:1; from about 1:3 to about 3:1; from about 1:2 to about 2:1; from about 1:1.5 to about 1.5:1; from about 1:1.3 to about 1.3:1 or from about 1:1.1 to about 1.1:11.
In certain embodiments, any of the following active agents can be used in the solid oral dosage form of the present invention: ACE inhibitors, adenohypophoseal hormones, adrenergic neuron blocking agents, adrenocortical steroids, inhibitors of the biosynthesis of adrenocortical steroids, alpha-adrenergic agonists, alpha-adrenergic antagonists, selective alpha-two-adrenergic agonists, analgesics, anti-pyretics, anti-inflammatory agents, androgens, local and general anesthetics, anti-addictive agents, anti-androgens, anti-arrhythmic agents, anti-asthmatic agents, anti-cholinergic agents, anti-cholinesterase agents, anti-coagulants, anti-diabetic agents, anti-diarrheal agents, anti-diuretic, anti-emetic agents, pro-kinetic agents, anti-epileptic agents, anti-estrogens, anti-fungal agents, anti-hypertensive agents, anti-microbial agents, anti-migraine agents, anti-muscarinic agents, anti-neoplastic agents, anti-parasitic agents, anti-parkinson's agents, anti-platelet agents, anti-progestins, anti-schizophrenia agents, anti-thyroid agents, anti-tussives, anti-viral agents, atypical anti-depressants, azaspirodecanediones, barbiturates, benzodiazepines, benzothiadiazides, beta-adrenergic agonists, beta-adrenergic antagonists, selective beta-one-adrenergic antagonists, selective beta-two-adrenergic agonists, bile salts, agents affecting volume and composition of body fluids, butyrophenones, agents affecting calcification, calcium channel blockers, cardiovascular drugs, cannabinoids, catecholamines and sympathomimetic drugs, cholinergic agonists, cholinesterase reactivators, contraceptive agents, dermatological agents, diphenylbutylpiperidines, diuretics, ergot alkaloids, estrogens, ganglionic blocking agents, ganglionic stimulating agents, hydantoins, agents for control of gastric acidity and treatment of peptic ulcers, hematopoietic agents, histamines, histamine antagonists, hormones, 5-hydroxytryptamine antagonists, drugs for the treatment of hyperlipoproteinemia, hypnotics, sedatives, immunosupressive agents, laxatives, methylxanthines, moncamine oxidase inhibitors, neuromuscular blocking agents, organic nitrates, opioid agonists, opioid antagonists, pancreatic enzymes, phenothiazines, progestins, prostaglandins, agents for the treatment of psychiatric disorders, psychotropics, retinoids, sodium channel blockers, agents for spasticity and acute muscle spasms, succinimides, testosterones, thioxanthines, thrombolytic agents, thyroid agents, tricyclic antidepressants, inhibitors of tubular transport of organic compounds, drugs affecting uterine motility, vasodilators, vitamins, and mixtures thereof.
In certain embodiments, the active agent is a drug susceptible to abuse (e.g., an opioid agonist). In such embodiments, the opioid agonist is selected from the group consisting of alfentanil, allylprodine, alphaprodine, anileridine, benzylmorphine, bezitramide, buprenorphine, butorphanol, clonitazene, codeine, desomorphine, dextromoramide, dezocine, diampromide, diamorphone, dihydrocodeine, dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, eptazocine, ethoheptazine, ethylmethylthiambutene, ethylmorphine, etonitazene, fentanyl, heroin, hydrocodone, hydromorphone, hydroxypethidine, isomethadone, ketobemidone, levorphanol, levophenacylmorphan, lofentanil, meperidine, meptazinol, metazocine, methadone, metopon, morphine, myrophine, nalbuphine, narceine, nicomorphine, norlevorphanol, normethadone, nalorphine, normorphine, norpipanone, opium, oxycodone, oxymorphone, papavereturn, pentazocine, phenadoxone, phenomorphan, phenazocine, phenoperidine, piminodine, piritramide, proheptazine, promedol, properidine, propiram, propoxyphene, sufentanil, tilidine, tramadol, pharmaceutically acceptable salts thereof, and mixtures thereof. In certain embodiments, the opioid agonist is selected from the group consisting of codeine, fentanyl, hydromorphone, hydrocodone, oxycodone, dihydrocodeine, dihydromorphine, morphine, tramadol, oxymorphone, pharmaceutically acceptable salts thereof, and mixtures thereof.
In certain embodiments, the opioid agonist is oxycodone or a pharmaceutically acceptable salt thereof (e.g., oxycodone hydrochloride) in an amount, e.g., from about 2.5 mg to about 320 mg, or in an amount of about 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 40 mg, 60 mg, 80 mg, 120 mg, 160 mg or 320 mg.
In certain embodiments of the present invention, wherein the active agent is oxycodone hydrochloride, the oxycodone hydrochloride has a 14-hydroxycodeinone level of less than about 25 ppm, less than about 15 ppm, less than about 10 ppm, less than about 5 ppm, less than about 2 ppm, less than about 1 ppm, less than about 0.5 ppm or less than about 0.25 ppm.
WO 2005/097801 A1, U.S. Pat. No. 7,129,248 B2 and US 2006/0173029 A1, all of which are hereby incorporated by reference, describe a process for preparing oxycodone hydrochloride having reduced levels of 14-hydroxycodeinone.
In certain embodiments, the opioid agonist is morphine or a pharmaceutically acceptable salt thereof (e.g., morphine sulfate) in an amount, e.g., of from about 15 mg to about 200 mg, or in an amount of about 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 40 mg, 50 mg, 60 mg, 80 mg, 100 mg, 120 mg, 150 mg or 200 mg.
The solid oral dosage forms of the present invention can provide a controlled release of the active agent. Certain embodiments can also provide a first portion of the active agent for immediate release and a second portion of the active agent for controlled release. For example, an immediate release portion of the drug can be layered over the particles of the dosage form or can be included in additional tablet excipients of which the particles are embedded.
In certain embodiments, the solid oral dosage form of the present invention comprises an active agent that is an opioid antagonist (with or without an opioid agonist). In such embodiments, the opioid antagonist is selected from the group consisting of amiphenazole, naltrexone, methylnaltrexone, naloxone, nalbuphine, nalorphine, nalorphine dinicotinate, nalmefene, nadide, levallorphan, cyclozocine, pharmaceutically acceptable salts thereof and mixtures thereof.
In certain embodiments, the solid oral dosage form of the present invention comprises an active agent that is a non-opioid analgesic. In such embodiments, the non-opioid analgesic is a non-steroidal anti-inflammatory agent selected from the group consisting of aspirin, celecoxib, ibuprofen, diclofenac, naproxen, benoxaprofen, flurbiprofen, fenoprofen, flubufen, ketoprofen, indoprofen, piroprofen, carprofen, oxaprozin, pramoprofen, muroprofen, trioxaprofen, suprofen, aminoprofen, tiaprofenic acid, fluprofen, bucloxic acid, indomethacin, sulindac, tolmetin, zomepirac, tiopinac, zidometacin, acemetacin, fentiazac, clidanac, oxpinac, mefenamic acid, meclofenamic acid, flufenamic acid, niflumic acid, tolfenamic acid, diflurisal, flufenisal, piroxicam, sudoxicam, isoxicam, pharmaceutically acceptable salts thereof and mixtures thereof.
In other embodiments, the present invention is directed to the dosage forms disclosed herein utilizing active agents such as benzodiazepines, barbiturates or amphetamines, their antagonists, or combinations thereof.
Benzodiazepines to be used in the present invention may be selected from alprazolam, bromazepam, chlordiazepoxide, clorazepate, diazepam, estazolam, flurazepam, halazepam, ketazolam, lorazepam, nitrazepam, oxazepam, prazepam, quazepam, temazepam, triazolam, and pharmaceutically acceptable salts, hydrates, and solvates and mixtures thereof. Benzodiazepine antagonists that can be used in the present invention include, but are not limited to, flumazenil and pharmaceutically acceptable salts, hydrates, and solvates.
Barbiturates to be used in the present invention include, but are not limited to, amobarbital, aprobarbotal, butabarbital, butalbital, methohexital, mephobarbital, metharbital, pentobarbital, phenobarbital, secobarbital and pharmaceutically acceptable salts, hydrates, and solvates mixtures thereof. Barbiturate antagonists that can be used in the present invention include, but are not limited to, amphetamines and pharmaceutically acceptable salts, hydrates, and solvates.
Stimulants to be used in the present invention include, but are not limited to, amphetamines, such as amphetamine, dextroamphetamine resin complex, dextroamphetamine, methamphetamine, methylphenidate and pharmaceutically acceptable salts, hydrates, and solvates and mixtures thereof. Stimulant antagonists that can be used in the present invention include, but are not limited to, benzodiazepines, and pharmaceutically acceptable salts, hydrates, and solvates as described herein.
Certain embodiments contain more than one active agent. For example, the dosage forms disclosed herein can contain both an opioid agonist and a non-opioid analgesic. In particular embodiments, the non-opioid analgesic is acetaminophen or a non-steroidal anti-inflammatory agent (e.g., ibuprofen, aspirin or diclofenac) and the opioid agonist is oxycodone, hydrocodone or pharmaceutically acceptable salts thereof (e.g., oxycodone hydrochloride or hydrocodone bitratrate).
The following examples are set forth to assist in understanding the invention and should not be construed as specifically limiting the invention described and claimed herein. Such variations of the invention, including the substitution of all equivalents now known or later developed, which would be within the purview of those skilled in the art, and changes in formulation or minor changes in experimental design, are to be considered to fall within the scope of the invention incorporated herein.
Oxycodone HCl-Eudragit NE granules were prepared with various additives to determine the effect the additives have on the adherence of Eudragit NE (NE) to Oxycodone HCl.
Oxycodone HCl was granulated with HPMC, Nonoxynol 9 or Carbopol in a high shear granulator to form seed granules These Oxycodone HCl seed granules were screened then further granulated/layered with Eudragit NE dispersion containing MC A15C (methyl cellulose) in a Rotor-granulator, followed by drying in the rotor-granulator. The ratios of the ingredients are shown in Table 1A below.
The granules were then tested for dissolution after tampering, and the results for Oxycodone-Eudragit NE granules with no additives, Oxycodone-Eudragit NE granules with HPMC, Oxycodone-Eudragit NE granules with Nonoxynol and Oxycodone-Eudragit NE granules with Carbopol are shown in
Since the Oxycodone HCl-Eudragit NE granules with Carbopol exhibited the best tamper resistance, Oxycodone-NE granules with Carbopol were prepared in accordance with Example 1A, with varying amounts of Oxycodone HCl, MC A40M, Eudragit NE and lactose to determine the effects on dissolution in SGF. The amounts of components of the various formulations prepared are shown in Table 1B below.
Dissolution was then tested, and the results are shown in
Oxycodone HCl-Eudragit granules were prepared in accordance with Example 1A, with varying amounts of components to determine the relationship between particle size and resistance to milling. Particle sizes greater than 600 μm and less than 600 μm were prepared. The amounts of components in the various formulations prepared are shown in Table 1C below.
Dissolution was then tested, and the results for granules greater than 600 μm and less than 600 μm are shown in
Next, the formulations were varied to test the effects of the amounts of Carbopol and lactose on the formulation. The amounts of components in the various formulations prepared are shown in Table 1D below.
Dissolution was then tested, and the results for granules greater than 600 μm and less than 600 μm are shown in
The Oxycodone HCl-Eudragit NE granules with Carbopol having a particle size of less than 600 μm were then tested for alcohol resistance in 40% EtOH/SGF. The results are shown in
In an attempt to improve alcohol resistance, the Oxycodone HCl-Eudragit NE granules with Carbopol of Example 1C were coated with an external layer of MC A15LV. The amounts of the components of the formulation are shown in Table 1E below.
This formulation was then tested for alcohol resistance and the data compared with the formulation without the external MC layer, as shown in
The formulation was then modified to replace the external coat of MC A15LV by wet granulation with extra-granular MCA40M (granulated with water). The amounts of this formulation, as compared to the formulation without the extra-granular MC, and with a higher level of extra-granular MC, are shown in Table 1F below.
The extra-granular MC A40M formulation was then tested for alcohol resistance, and the results are shown in
Next, Carbopol was added to the extra-granular layer in the amounts shown in Table 1G below.
Oxycodone HCl-Eudragit NE granules were prepared with various levels of additives to determine the effect the additives have on the adherence of Eudragit NE to MC A40M and consequently on alcohol resistance
The extra-granular MCA40M/Carbopol formulation was then tested for alcohol resistance, and the results are shown in
To determine the effect of the amount of Carbopol on alcohol resistance, the amount of Carbopol was doubled, as shown in Table 1F below.
The extra-granular MCA40M/Carbopol formulation was then tested for alcohol resistance, and the results are shown in
The dissolution of the 4.9% Carbopol (external layer) formulation was then tested, and the results are shown in
The formulation was then tested for resistance to milling, and the results are shown in
Tablet formulations were prepared as follows:
Equipment
Vector GMX Micro High-Shear granulator
Glatt Fluid Bed Dryer—Model Versa Glatt
Comil Comminuting Mill
Stainless Steel Screens—US Std. #18, #30
Procedure
Equipment
Vector VFC-Lab3 Flo-Coater with GXR-35 rotor—also called Rotor-granulator
Stainless Steel Screen—US Std. #30
Hotpack Tray Dryer
Procedure
Equipment
Vector GMX Micro High-Shear granulator
Glatt Fluid Bed Dryer—Model Versa Glatt
Comil Comminuting Mill
Stainless Steel Screens—US Std. #18
Procedure
The amounts of the components in the tablet formulation are shown in Table 2 below.
Dissolution of the prepared tablets was performed as follows:
The dissolution of the tablet formulation, intact in SGF and crushed and milled in SGF is shown in
The tablets of Example 2 were tested for extractability by small volume of various solvents at various temperatures. The studies were performed as follows:
Small Volume Extraction:
The results after 10 minutes and 60 minutes are shown in
Syringability:
Room Temperature Samples
| Number | Name | Date | Kind |
|---|---|---|---|
| 3065143 | Christenson et al. | Nov 1962 | A |
| 3096248 | Rudzki | Jul 1963 | A |
| 3133132 | Loeb et al. | May 1964 | A |
| 3173876 | Zobrist et al. | Mar 1965 | A |
| 3260646 | Paulsen | Jul 1966 | A |
| 3276586 | Rosaen | Oct 1966 | A |
| 3400197 | Lippman | Sep 1968 | A |
| 3541005 | Strathmann et al. | Nov 1970 | A |
| 3541006 | Bixler et al. | Nov 1970 | A |
| 3546876 | Fokker et al. | Dec 1970 | A |
| 3845770 | Theeuwes et al. | Nov 1974 | A |
| 3879555 | Pachter et al. | Apr 1975 | A |
| 3916889 | Russell | Nov 1975 | A |
| 3965256 | Leslie | Jun 1976 | A |
| 3980766 | Shaw et al. | Sep 1976 | A |
| 4063064 | Saunders et al. | Dec 1977 | A |
| 4070494 | Hollmeister et al. | Jan 1978 | A |
| 4088864 | Theeuwes et al. | May 1978 | A |
| 4160020 | Ayer et al. | Jul 1979 | A |
| 4175119 | Porter | Nov 1979 | A |
| 4200098 | Ayer et al. | Apr 1980 | A |
| 4235870 | Leslie | Nov 1980 | A |
| 4285987 | Ayer et al. | Aug 1981 | A |
| 4293539 | Ludwig et al. | Oct 1981 | A |
| 4366310 | Leslie | Dec 1982 | A |
| 4385057 | Bjork et al. | May 1983 | A |
| 4389393 | Schor et al. | Jun 1983 | A |
| 4424205 | LaHann et al. | Jan 1984 | A |
| 4443428 | Oshlack et al. | Apr 1984 | A |
| 4457933 | Gordon et al. | Jul 1984 | A |
| 4459278 | Porter | Jul 1984 | A |
| 4588580 | Gale et al. | May 1986 | A |
| 4599342 | LaHann | Jul 1986 | A |
| 4610870 | Jain et al. | Sep 1986 | A |
| 4612008 | Wong et al. | Sep 1986 | A |
| 4629623 | Balazs et al. | Dec 1986 | A |
| 4666705 | DeCrosta et al. | May 1987 | A |
| 4764378 | Keith et al. | Aug 1988 | A |
| 4765989 | Wong et al. | Aug 1988 | A |
| 4769372 | Kreek | Sep 1988 | A |
| 4785000 | Kreek et al. | Nov 1988 | A |
| 4806341 | Chien et al. | Feb 1989 | A |
| 4812446 | Brand | Mar 1989 | A |
| 4834984 | Goldie et al. | May 1989 | A |
| 4844909 | Goldie et al. | Jul 1989 | A |
| 4861598 | Oshlack | Aug 1989 | A |
| 4957681 | Klimesch et al. | Sep 1990 | A |
| 4970075 | Oshlack | Nov 1990 | A |
| 4990341 | Goldie et al. | Feb 1991 | A |
| 4992277 | Sangekar et al. | Feb 1991 | A |
| 5026556 | Drust et al. | Jun 1991 | A |
| 5059600 | Gawin et al. | Oct 1991 | A |
| 5069909 | Sharma et al. | Dec 1991 | A |
| 5111942 | Bernardin | May 1992 | A |
| 5113585 | Rogers et al. | May 1992 | A |
| 5114942 | Gawin et al. | May 1992 | A |
| 5130311 | Guillaumet et al. | Jul 1992 | A |
| 5149538 | Granger et al. | Sep 1992 | A |
| 5169645 | Shukla et al. | Dec 1992 | A |
| 5202128 | Morella et al. | Apr 1993 | A |
| 5215758 | Krishnamurthy | Jun 1993 | A |
| 5225199 | Hidaka et al. | Jul 1993 | A |
| 5232685 | Speck et al. | Aug 1993 | A |
| 5232934 | Downs | Aug 1993 | A |
| 5240711 | Hille et al. | Aug 1993 | A |
| 5266331 | Oshlack et al. | Nov 1993 | A |
| 5273758 | Royce | Dec 1993 | A |
| 5273760 | Oshlack et al. | Dec 1993 | A |
| 5286493 | Oshlack et al. | Feb 1994 | A |
| 5290816 | Blumberg | Mar 1994 | A |
| 5300302 | Tachon et al. | Apr 1994 | A |
| 5321012 | Mayer et al. | Jun 1994 | A |
| 5324351 | Oshlack et al. | Jun 1994 | A |
| 5330766 | Morella et al. | Jul 1994 | A |
| 5356467 | Oshlack et al. | Oct 1994 | A |
| 5376705 | Leys et al. | Dec 1994 | A |
| 5378474 | Morella et al. | Jan 1995 | A |
| 5399351 | Leschiner et al. | Mar 1995 | A |
| 5403868 | Reid et al. | Apr 1995 | A |
| 5409944 | Black et al. | Apr 1995 | A |
| 5411745 | Oshlack et al. | May 1995 | A |
| 5422123 | Conte et al. | Jun 1995 | A |
| 5425950 | Dandiker et al. | Jun 1995 | A |
| 5436265 | Black et al. | Jul 1995 | A |
| 5472712 | Oshlack et al. | Dec 1995 | A |
| 5472943 | Crain et al. | Dec 1995 | A |
| 5474995 | Ducharme et al. | Dec 1995 | A |
| 5478577 | Sackler et al. | Dec 1995 | A |
| 5500227 | Oshlack et al. | Mar 1996 | A |
| 5502058 | Mayer et al. | Mar 1996 | A |
| 5505959 | Tachon et al. | Apr 1996 | A |
| 5508042 | Oshlack et al. | Apr 1996 | A |
| 5508043 | Krishnamurthy | Apr 1996 | A |
| 5510368 | Lau et al. | Apr 1996 | A |
| 5514680 | Weber et al. | May 1996 | A |
| 5521213 | Prasit et al. | May 1996 | A |
| 5489439 | Bola | Jun 1996 | A |
| 5536507 | Abramowitz et al. | Jul 1996 | A |
| 5536752 | Ducharme et al. | Jul 1996 | A |
| 5549912 | Oshlack et al. | Aug 1996 | A |
| 5549913 | Colombo et al. | Aug 1996 | A |
| 5550142 | Ducharme et al. | Aug 1996 | A |
| 5552422 | Gauthier et al. | Sep 1996 | A |
| 5556838 | Mayer et al. | Sep 1996 | A |
| 5567439 | Myers et al. | Oct 1996 | A |
| 5580578 | Oshlack et al. | Dec 1996 | A |
| 5593695 | Merrill et al. | Jan 1997 | A |
| 5593994 | Batt et al. | Jan 1997 | A |
| 5604253 | Lau et al. | Feb 1997 | A |
| 5604260 | Guay et al. | Feb 1997 | A |
| 5616601 | Khanna et al. | Apr 1997 | A |
| 5593694 | Hayashida et al. | Jun 1997 | A |
| 5639476 | Oshlack et al. | Jun 1997 | A |
| 5639789 | Lau et al. | Jun 1997 | A |
| 5654005 | Chen et al. | Aug 1997 | A |
| 5656295 | Oshlack et al. | Aug 1997 | A |
| 5667805 | Merrill et al. | Sep 1997 | A |
| 5672360 | Sackler et al. | Sep 1997 | A |
| 5676972 | Galiatsatos et al. | Oct 1997 | A |
| 5679650 | Fukunaga et al. | Oct 1997 | A |
| 5681585 | Oshlack et al. | Oct 1997 | A |
| 5695781 | Zhang et al. | Dec 1997 | A |
| 5702725 | Merrill et al. | Dec 1997 | A |
| 5730716 | Beck et al. | Mar 1998 | A |
| 5741524 | Staniforth et al. | Apr 1998 | A |
| 5762963 | Byas-Smith | Jun 1998 | A |
| 5766623 | Aryes et al. | Jun 1998 | A |
| 5788987 | Busetti et al. | Aug 1998 | A |
| 5811126 | Krishnamurthy | Sep 1998 | A |
| 5811388 | Friend et al. | Sep 1998 | A |
| 5814336 | Kelm et al. | Sep 1998 | A |
| 5837379 | Chen et al. | Nov 1998 | A |
| 5843480 | Miller et al. | Dec 1998 | A |
| 5849240 | Miller et al. | Dec 1998 | A |
| 5866164 | Kuczynski et al. | Feb 1999 | A |
| 5879705 | Heafield et al. | Mar 1999 | A |
| 5891471 | Miller et al. | Apr 1999 | A |
| 5891919 | Blum et al. | Apr 1999 | A |
| 5914131 | Miller et al. | Jun 1999 | A |
| 5945125 | Kin | Aug 1999 | A |
| 5948787 | Merrill et al. | Sep 1999 | A |
| 5958452 | Oshlack et al. | Sep 1999 | A |
| 5958459 | Chasin et al. | Sep 1999 | A |
| 5965163 | Miller et al. | Sep 1999 | A |
| 5965161 | Oshlack et al. | Oct 1999 | A |
| 5968551 | Oshlack et al. | Oct 1999 | A |
| 6024982 | Oshlack et al. | Feb 2000 | A |
| 6103261 | Chasin et al. | Aug 2000 | A |
| 6120751 | Unger | Sep 2000 | A |
| 6124282 | Sellers et al. | Sep 2000 | A |
| 6126969 | Shah et al. | Oct 2000 | A |
| 6136864 | Nichols et al. | Oct 2000 | A |
| 6143322 | Sackler et al. | Nov 2000 | A |
| 6153621 | Hamann | Nov 2000 | A |
| 6162467 | Miller et al. | Dec 2000 | A |
| 6210712 | Edgren et al. | Apr 2001 | B1 |
| 6210714 | Oshlack et al. | Apr 2001 | B1 |
| 6223075 | Beck et al. | Apr 2001 | B1 |
| 6228863 | Palermo et al. | May 2001 | B1 |
| 6245357 | Edgren et al. | Jun 2001 | B1 |
| 6251430 | Zhang et al. | Jun 2001 | B1 |
| 6277398 | Caruso | Aug 2001 | B1 |
| 6294194 | Horhota et al. | Sep 2001 | B1 |
| 6309668 | Bastin et al. | Oct 2001 | B1 |
| 6348469 | Seth | Feb 2002 | B1 |
| 6352721 | Faour | Mar 2002 | B1 |
| 6365185 | Ritschel et al. | Apr 2002 | B1 |
| 6372254 | Ting et al. | Apr 2002 | B1 |
| 6375957 | Kaiko et al. | Apr 2002 | B1 |
| 6403056 | Unger | Jun 2002 | B1 |
| 6419954 | Chu | Jul 2002 | B1 |
| 6419960 | Krishnamurthy et al. | Jul 2002 | B1 |
| 6436441 | Sako et al. | Aug 2002 | B1 |
| 6440464 | Hsia et al. | Aug 2002 | B1 |
| 6455537 | Cooper | Sep 2002 | B1 |
| 6485748 | Chen et al. | Nov 2002 | B1 |
| 6488963 | McGinity | Dec 2002 | B1 |
| 6491949 | Faour et al. | Dec 2002 | B2 |
| 6559159 | Carroll et al. | May 2003 | B2 |
| 6572885 | Oshlack et al. | Jun 2003 | B2 |
| 6593367 | Dewey et al. | Jul 2003 | B1 |
| 6627635 | Palermo et al. | Sep 2003 | B2 |
| 6696088 | Oshlack et al. | Feb 2004 | B2 |
| 6723340 | Gusler et al. | Apr 2004 | B2 |
| 6730321 | Ting et al. | May 2004 | B2 |
| 6733783 | Oshlack et al. | May 2004 | B2 |
| 6761895 | Sawada et al. | Jul 2004 | B2 |
| 6808720 | Unger | Oct 2004 | B2 |
| 6955821 | Davis et al. | Oct 2005 | B2 |
| 6987082 | Tijsma et al. | Jan 2006 | B2 |
| 6995169 | Chapleo et al. | Feb 2006 | B2 |
| RE39239 | Busetti et al. | Aug 2006 | E |
| 7141250 | Oshlack | Nov 2006 | B2 |
| 7144587 | Oshlack et al. | Dec 2006 | B2 |
| 7157103 | Sackler | Jan 2007 | B2 |
| 7201920 | Kumar et al. | Apr 2007 | B2 |
| 7276250 | Baichwal et al. | Oct 2007 | B2 |
| 7332182 | Sackler | Feb 2008 | B2 |
| 7399488 | Hirsch et al. | Jul 2008 | B2 |
| 7510726 | Kumar et al. | Mar 2009 | B2 |
| 7718194 | Chenevier et al. | May 2010 | B2 |
| 7727557 | Sackler | Jun 2010 | B2 |
| 7776314 | Bartholomaus | Aug 2010 | B2 |
| 7842307 | Oshlack et al. | Nov 2010 | B2 |
| 7842311 | Oshlack et al. | Nov 2010 | B2 |
| 7943174 | Oshlack et al. | May 2011 | B2 |
| 7981439 | Kumar et al. | Jul 2011 | B2 |
| 8017148 | Sackler | Sep 2011 | B2 |
| 8075872 | Arkenau-Maric et al. | Dec 2011 | B2 |
| 8101630 | Kumar et al. | Jan 2012 | B2 |
| 8114383 | Bartholomaus | Feb 2012 | B2 |
| 8114384 | Arkenau et al. | Feb 2012 | B2 |
| 8143267 | Burch et al. | Mar 2012 | B2 |
| 8192722 | Arkenau-Maric et al. | Jun 2012 | B2 |
| 8193209 | Burch et al. | Jun 2012 | B2 |
| 8293277 | Swanson et al. | Oct 2012 | B2 |
| 8309060 | Bartholomaus et al. | Nov 2012 | B2 |
| 8323692 | Frisbee | Dec 2012 | B2 |
| 8337888 | Wright et al. | Dec 2012 | B2 |
| 8389007 | Wright et al. | Mar 2013 | B2 |
| 8394408 | Han et al. | Mar 2013 | B2 |
| 8409616 | Kumar et al. | Apr 2013 | B2 |
| 8524275 | Oshlack et al. | Sep 2013 | B2 |
| 8529948 | Wright et al. | Sep 2013 | B1 |
| 8551520 | Oshlack et al. | Oct 2013 | B2 |
| 8609143 | Fischer et al. | Dec 2013 | B2 |
| 8609683 | Wright et al. | Dec 2013 | B2 |
| 8617600 | Bhatt et al. | Dec 2013 | B2 |
| 8637540 | Kumar et al. | Jan 2014 | B2 |
| 8647667 | Oshlack et al. | Feb 2014 | B2 |
| 8652497 | Sackler | Feb 2014 | B2 |
| 8652515 | Sackler | Feb 2014 | B2 |
| 8652529 | Guimberteau et al. | Feb 2014 | B2 |
| 8871265 | Wright et al. | Oct 2014 | B2 |
| 8999961 | Wright et al. | Apr 2015 | B2 |
| 9034376 | Wright et al. | May 2015 | B2 |
| 9040084 | Wright et al. | May 2015 | B2 |
| 9044435 | Wright et al. | Jun 2015 | B2 |
| 9060976 | Wright et al. | Jun 2015 | B2 |
| 9233073 | Sackler | Jan 2016 | B2 |
| 9616030 | Shmeis | Apr 2017 | B2 |
| 20010031278 | Oshlack et al. | Oct 2001 | A1 |
| 20020028240 | Sawada et al. | Mar 2002 | A1 |
| 20020187192 | Joshi et al. | Dec 2002 | A1 |
| 20030004177 | Kao et al. | Jan 2003 | A1 |
| 20030021841 | Matharu et al. | Jan 2003 | A1 |
| 20030026838 | Farrell | Feb 2003 | A1 |
| 20030035839 | Hirsh et al. | Feb 2003 | A1 |
| 20030059471 | Compton et al. | Mar 2003 | A1 |
| 20030064099 | Oshlack et al. | Apr 2003 | A1 |
| 20030064122 | Goldberg et al. | Apr 2003 | A1 |
| 20030068276 | Hughes et al. | Apr 2003 | A1 |
| 20030068370 | Sackler | Apr 2003 | A1 |
| 20030068371 | Oshlack et al. | Apr 2003 | A1 |
| 20030068375 | Wright et al. | Apr 2003 | A1 |
| 20030068392 | Sackler | Apr 2003 | A1 |
| 20030082230 | Baichwal et al. | May 2003 | A1 |
| 20030091625 | Hariharan et al. | May 2003 | A1 |
| 20030092724 | Kao et al. | May 2003 | A1 |
| 20030124061 | Roberts | Jul 2003 | A1 |
| 20030124185 | Oshlack et al. | Jul 2003 | A1 |
| 20030125347 | Anderson et al. | Jul 2003 | A1 |
| 20030126428 | Liu et al. | Jul 2003 | A1 |
| 20030170181 | Midha | Sep 2003 | A1 |
| 20030190362 | Sackler et al. | Oct 2003 | A1 |
| 20030206954 | Lerner et al. | Nov 2003 | A1 |
| 20030232081 | Doshi et al. | Dec 2003 | A1 |
| 20040010000 | Ayer et al. | Jan 2004 | A1 |
| 20040047907 | Oshlack et al. | Mar 2004 | A1 |
| 20040110781 | Harmon et al. | Jun 2004 | A1 |
| 20040126428 | Hughes et al. | Jul 2004 | A1 |
| 20040131552 | Boehm | Jul 2004 | A1 |
| 20040151791 | Mayo-Alvarez et al. | Aug 2004 | A1 |
| 20040202717 | Mehtha | Oct 2004 | A1 |
| 20040224020 | Schoenhard | Nov 2004 | A1 |
| 20040228802 | Chang et al. | Nov 2004 | A1 |
| 20040241234 | Vikov | Dec 2004 | A1 |
| 20040253310 | Fischer et al. | Dec 2004 | A1 |
| 20040266807 | Oshlack et al. | Dec 2004 | A1 |
| 20050020613 | Boehm et al. | Jan 2005 | A1 |
| 20050031546 | Bartholomaus et al. | Feb 2005 | A1 |
| 20050063909 | Wright et al. | Mar 2005 | A1 |
| 20050106249 | Hwang et al. | May 2005 | A1 |
| 20050112067 | Kumar et al. | May 2005 | A1 |
| 20050112201 | Baichwal et al. | May 2005 | A1 |
| 20050118267 | Baichwal et al. | Jun 2005 | A1 |
| 20050158382 | Cruz et al. | Jul 2005 | A1 |
| 20050163717 | Anderson et al. | Jul 2005 | A1 |
| 20050186139 | Bartholomaeus et al. | Aug 2005 | A1 |
| 20050191351 | Kidane | Sep 2005 | A1 |
| 20050214223 | Bartholomaeus et al. | Sep 2005 | A1 |
| 20050232987 | Srinivasan et al. | Oct 2005 | A1 |
| 20050236741 | Arkenau et al. | Oct 2005 | A1 |
| 20050276853 | Baichwal et al. | Dec 2005 | A1 |
| 20060002860 | Bartholomaus et al. | Jan 2006 | A1 |
| 20060018837 | Preston et al. | Jan 2006 | A1 |
| 20060039864 | Bartholomaus et al. | Feb 2006 | A1 |
| 20060165790 | Walden et al. | Jul 2006 | A1 |
| 20060188447 | Arkenau-Maric et al. | Aug 2006 | A1 |
| 20060193782 | Bartholomaus et al. | Aug 2006 | A1 |
| 20060210631 | Patel et al. | Sep 2006 | A1 |
| 20060240107 | Lenaerts | Oct 2006 | A1 |
| 20060251721 | Cruz et al. | Nov 2006 | A1 |
| 20070003616 | Arkenau-Maric et al. | Jan 2007 | A1 |
| 20070003617 | Fischer et al. | Jan 2007 | A1 |
| 20070020335 | Chen et al. | Jan 2007 | A1 |
| 20070110807 | Vergnault et al. | May 2007 | A1 |
| 20070166234 | Kumar et al. | Jul 2007 | A1 |
| 20070183980 | Arkenau-Maric et al. | Aug 2007 | A1 |
| 20070224129 | Guimberteau et al. | Sep 2007 | A1 |
| 20070264327 | Kumar et al. | Nov 2007 | A1 |
| 20080026060 | Zerbe et al. | Jan 2008 | A1 |
| 20080057123 | Grenier et al. | Mar 2008 | A1 |
| 20080063725 | Guimbertau et al. | Mar 2008 | A1 |
| 20080069891 | Habib | Mar 2008 | A1 |
| 20080090892 | Casteel et al. | Apr 2008 | A1 |
| 20080095843 | Nutalapati et al. | Apr 2008 | A1 |
| 20080107732 | Dharmadhikari et al. | May 2008 | A1 |
| 20080147044 | Palmer et al. | Jun 2008 | A1 |
| 20080175908 | Liu et al. | Jul 2008 | A1 |
| 20080176955 | Heck et al. | Jul 2008 | A1 |
| 20080187581 | Gore et al. | Aug 2008 | A1 |
| 20080254123 | Fischer et al. | Oct 2008 | A1 |
| 20080260815 | Hayes et al. | Oct 2008 | A1 |
| 20080260824 | Nangia et al. | Oct 2008 | A1 |
| 20080311191 | Nangia et al. | Dec 2008 | A1 |
| 20090011019 | Jahagirdar et al. | Jan 2009 | A1 |
| 20090022798 | Rosenberg et al. | Jan 2009 | A1 |
| 20090081290 | McKenna et al. | Mar 2009 | A1 |
| 20090169587 | Baichwal et al. | Jul 2009 | A1 |
| 20090215808 | Yum et al. | Aug 2009 | A1 |
| 20090232885 | Venkatesh et al. | Sep 2009 | A1 |
| 20090269393 | Kashid | Oct 2009 | A1 |
| 20100015222 | Han et al. | Jan 2010 | A1 |
| 20100015223 | Cailly-Dufestel et al. | Jan 2010 | A1 |
| 20100221293 | Cruz et al. | Sep 2010 | A1 |
| 20110020451 | Bartholomaus et al. | Jan 2011 | A1 |
| 20110223244 | Liversidge | Sep 2011 | A1 |
| 20110229564 | Desai | Sep 2011 | A1 |
| 20110262532 | Oshlack et al. | Oct 2011 | A1 |
| 20120164220 | Huang | Jun 2012 | A1 |
| 20120244216 | Shah et al. | Sep 2012 | A1 |
| 20130209525 | Cruz et al. | Aug 2013 | A1 |
| 20130217716 | Wright et al. | Aug 2013 | A1 |
| 20130245055 | Wright et al. | Sep 2013 | A1 |
| 20140056979 | Huang | Feb 2014 | A1 |
| 20140213606 | Wright et al. | Jul 2014 | A1 |
| 20140371257 | Wright et al. | Dec 2014 | A1 |
| 20150005331 | Wright et al. | Jan 2015 | A1 |
| 20150031718 | Wright et al. | Jan 2015 | A1 |
| 20150140083 | Wright et al. | May 2015 | A1 |
| 20150147391 | Wright et al. | May 2015 | A1 |
| 20150148319 | Wright et al. | May 2015 | A1 |
| 20150182628 | Wright et al. | Jul 2015 | A1 |
| Number | Date | Country |
|---|---|---|
| 2569743 | Dec 2005 | CA |
| 2594373 | Aug 2006 | CA |
| 2746888 | Jun 2010 | CA |
| 2764517 | Dec 2010 | CA |
| 0111144 | Oct 1983 | EP |
| 0318262 | May 1989 | EP |
| 0661045 | May 1995 | EP |
| 698389 | Feb 1996 | EP |
| 0647448 | Feb 2001 | EP |
| 1293195 | Mar 2003 | EP |
| 1897544 | Mar 2008 | EP |
| 1897545 | Dec 2008 | EP |
| 2457563 | May 2012 | EP |
| 0107950 | Jun 1991 | WO |
| 199310765 | Jun 1993 | WO |
| 9520947 | Aug 1995 | WO |
| 9712605 | Apr 1997 | WO |
| 9737689 | Oct 1997 | WO |
| 9748385 | Dec 1997 | WO |
| 9749384 | Dec 1997 | WO |
| 9920255 | Apr 1999 | WO |
| 9932119 | Jul 1999 | WO |
| 9932120 | Jul 1999 | WO |
| 9944591 | Sep 1999 | WO |
| 2000033835 | Jun 2000 | WO |
| 2001008661 | Feb 2001 | WO |
| 2001056544 | Aug 2001 | WO |
| 2001058447 | Aug 2001 | WO |
| 2001076576 | Oct 2001 | WO |
| 2002036099 | May 2002 | WO |
| 2002087558 | Nov 2002 | WO |
| 2002094254 | Nov 2002 | WO |
| 2003013479 | Feb 2003 | WO |
| 2003015531 | Feb 2003 | WO |
| 2003024430 | Mar 2003 | WO |
| 2003026743 | Apr 2003 | WO |
| 2003035029 | May 2003 | WO |
| 2003092676 | Nov 2003 | WO |
| 2004026256 | Jan 2004 | WO |
| 2004026283 | Apr 2004 | WO |
| 2004037259 | May 2004 | WO |
| 2005007135 | Jan 2005 | WO |
| 2005046727 | May 2005 | WO |
| 2005053587 | Jun 2005 | WO |
| 2006002884 | Jan 2006 | WO |
| 2007150074 | Dec 2007 | WO |
| 2007150075 | Dec 2007 | WO |
| 2008023261 | Feb 2008 | WO |
| 2009023672 | Feb 2009 | WO |
| 2009114648 | Sep 2009 | WO |
| 2010019279 | Feb 2010 | WO |
| 2010078486 | Jul 2010 | WO |
| 2010083894 | Jul 2010 | WO |
| 2010141505 | Dec 2010 | WO |
| 2011154414 | Dec 2011 | WO |
| 2012076907 | Jun 2012 | WO |
| WO-2012076907 | Jun 2012 | WO |
| 2012131463 | Oct 2012 | WO |
| 2013171146 | Nov 2013 | WO |
| Entry |
|---|
| Eager Polymers (Material Safety Data Sheet for CAB-O-SIL, M-5 Grade, [Retrieved from internet <URL: http://www.eagerplastics.com/msdscabosil.htm >], (revised May 6, 2015), 5 pages). |
| Londhe et al., Formulation Development and Evaluation of Fast Dissolving Films of Telmisartan, Indian Journal of Pharmaceutical Sciences (Mar.-Apr. 2012), www.ijpsonline.com, pp. 122-126 (Year: 2012). |
| Lubrizol, Carbopol 71G NF Polymer, [Retrieved from internet <URL: https://www.lubrizol.com/Life-Sciences/Products/Carbopol-Polymer-Products/Carbopol-71G-NF-Polymer >], [Downloaded Aug. 27, 2018], 2 pages (Year: 2018). |
| International Search Report for International Application No. PCT/US2014/028260 filed on Mar. 14, 2014, dated Jul. 25, 2014, 4 pgs. |
| Written Opinion of the International Searching Authority for International Application No. PCT/US2014/028260 filed on Mar. 15, 2014, dated Jul. 25, 2014, 15 pgs. |
| Ansel, Howard C., et al., Pharmaceutical Dosage Forms and Drug Delivery Systems, 7th Edition, 1999, pp. 1-2, 23-163, 179-243, 397-449, 552-562, Lippincott Williams & Wilkins, United States. |
| Apicella, A., “Poly(ethylene oxide)(PEO) and Different Molecular Weight PEO Blends Monolithic Devices for Drug Release,” Biomaterials, vol. 14, No. 2, 1993, pp. 83-90. |
| Apicella, et al., “Poly(ethylene oxide)-Based Delivery Systems,” Polymeric Drugs and Drug Administration, ACS Symposium Series 545, Chapter 9 (1994), pp. 111-125. |
| Apicella, et al. “Poly(ethylene oxide)(PEO) Constant Release Monolithic Devices,” Polymers in Medicine: Biomedical and Pharmaceutical Applications, Chapter 3 (1992), pp. 23-37. |
| Aulton Michael E., et al., Pharmaceutics, The Science of Dosage Form Design, Reprinted 2000, pp. 1-2, 17-37, 62-80, 131-211, 304-321, 359-380, 550-677, Churchill Livingston, China. |
| Bettini, et al., “Translocation of drug particles in HPMC matrix gel layer: effect of drug solubility and influence on release rate,” Journal of Controlled Release, vol. 70, No. 3, Feb. 2001, pp. 383-391. |
| Bhatia, R., “Effect of Molecular Mass, Concentration and Temperature on the Rheological Properties of Non-Newtonian Agueous Polymeric Solutions,” 114, 2011, 202 pgs. |
| Chien, Yie W., et al., “Syringeability of Nonaqueous Parenteral Formulations—Development and Evaluation of Testing Apparatus,” Journal of Parenteral Science and Technology, vol. 35, No. 6, Nov. 1981, pp. 281-284. |
| Deighan, C.J., et al., “Rhabdomyolysis and Acute Renal Failure Resulting From Alcohol and Drug Abuse,” QJ Med., vol. 93, 2000, pp. 29-33. |
| Dexter, M.B., et al., “The Evaluation of the Force to Expel Oily Injection Vehicles from Syringes,” J. Pharm. Pharmacol., vol. 31, Aug. 1979, The Pharmaceutical Society of Great Britain, pp. 497-500. |
| Gennaro, Alfonso, Remington: The Science and Practice of Pharmacy, 20th Edition, 2000, pp. 1-3, 335-355, 654-666, 669-752, 780-820, 858-929, 995-10004, 1098-1155, 1175-1182, 1395-1399, 2037-2038, Lippincott Williams & Wilkins, Baltimore, MD, United States. |
| Handbook of Pharmaceutical Excipients, 1986, pp. 234-239, American Pharmaceutical Association, Washington D.C., United States. |
| Hardman, Joel G., et al., Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Edition, 1996, pp. 3-27, 521-555, 557-577, McGraw-Hill, United States. |
| Hariharan, M., and Gupta, V.K., “A Novel Compression-Coated Tablet Dosage Form,” Pharmaceutical Technology Yearbook, 2001, Jan. 1, 2001, pp. 14-19. |
| Hem, Stanley, et al., “Tissue Irritation Evaluation of Potential Parenteral Vehicles,” Drug Development Communications, 1:5, 1974, pp. 471-477, Marcel Dekker, Inc. |
| Heng, Paul, et al., “Role of Surfactant on Drug Release from Tablets”, Drug Development and Industrial Pharmacy, Oct. 20, 2008, pp. 951-962, Taylor & Francis, London, United Kingdom. |
| Huang, H., et al., “Preparation of Controlled Release Oral Dosage Forms by Low Temperature Melt Extrusion,” The AAPS Journal, AAPS PharmaSci, 2000, 2(S1), 3 pgs. |
| Industrial and Engineering Chemistry I/EC, Golden Anniversary Year 50, Pattern for Progress, vol. 50, No. 1, Jan. 10, 1958, pp. 8-11, American Chemical Society, Easton, PA, United States. |
| Kalant, H., et al., “Death in Amphetamine Users: Causes and Rates,” CMA Journal, vol. 112, Feb. 8, 1975, pp. 299-304. |
| Kibbe, Arthur, H., “Polyethylene Oxide,” Handbook of Pharmaceutical Excipients, Third Edition, 2000, pp. 399-400, PhP Pharmaceutical Press, London, United Kingdom. |
| Kim, C., “Drug Release from Compressed Hydrophilic POLYOX-WSR Tablets,” Journal of Pharmaceutical Sciences, vol. 84, No. 3, Mar. 1995, pp. 303-306. |
| Maggi, L., et al, “Dissolution Behaviour of Hydrophilic Matrix Tablets Containing Two Different Polyethylene Oxides (PEOs) for the Controlled Release of a Water-Soluble Drug,” Biomaterials, vol. 23, pp. 1113-1119 (2002). |
| Medical Economics Company, Inc., The 1997 Physician's Desk Reference (“PDR”) entry for OXYCONTIN®, 51st edition, Nov. 1996, Montvale, NJ pp. 2163-2164. |
| Meier, Barry, “U.S. Asks Painkiller Maker to Help Curb Wide Abuse,” The New York Times, May 1, 2001, 3 pgs. |
| Modern Pharmaceutics, 3rd Edition, Drugs and the Pharmaceutical Sciences, vol. 72, 1996, pp. 21-73, 75-119, 121-153, 155-178, 333-394, 441-487, 575-609, 727-772, Marcel Dekker, Inc., United States. |
| Moroni, et al., “Application of Poly(oxyethylene) Homopolymers in Sustained Release Solid Formulation,” Drug Dev. and Indus. Pharmacy, 21(12), pp. 1411-1428 (1995). |
| Philip, George, et al., “The Human Nasal Response to Capsaicin,” J. Allergy Clin. Immonul., vol. 94, No. 6, Part 1, Dec. 1994, pp. 1035-1045, Mosy-Year Book, Inc., Baltimore, MD, United States. |
| Poynton, Charles, Digital Video and HDTV Algorithms and Interfaces, The CIE System of Colorimetry, 2003, pp. 228-229, Morgan Kaufmann Publishers, San Francisco, United States. |
| Prescribing Information for Concerta Extended-Release Tablets, Nov. 2010, pp. 1-9 , Ortho-McNeil-Janssen Pharmaceuticals, Inc., Titusville, United States. |
| Product webpage for EUDRAGIT RS 30 D [online] (Apr. 30, 2010), retrieved from the internet on (Dec. 10, 2014) from URL, http://web.archive.org/web/20100430062425/http://eudragit.evonik.com/prouct/eudragit/en/products-services/eudragit-products/sustained-release-formulations/rs-30-d/pages/default.aspx>. |
| Sarkar, N., “Kinetics of thermal gelation of methylcellulose and hydroxypropylmethylcellulose in aqueous solutions,” Carbohydrate Polymers, vol. 26, No. 3, Jan. 1995, pp. 195-203. |
| Sarkar, N., “Thermal Gelation Properties of Methyl and Hydroxypropyl Methylcellulose,” Journal of Polymer Science, vol. 24, No. 4, Aug. 1979, pp. 1073-1087. |
| Stafford, J.W., et al., “Temperature dependence of the disintegration times of compressed tablets containing hydroxypropylcellulose as binder,” Journal of Pharmacy and Pharmacology, vol. 30, No. 1, Sep. 1978, pp. 1-5, John Wiley & Sons, New York, United States. |
| The 1997 Physician's Desk Reference (“PDR”), 51st edition, Nov. 1996, pp. 955-957, 988-989, 2163-2167, 2366-2367, Medical Economics Company, Inc., Montvale, NJ, United States. |
| The Merck Index, 14th Edition, Entry Nos. 4785, 4803, 6276 and 9566, Whitehouse Station, New Jersey, USA, 2006. |
| Tough, Paul, “The Alchemy of Oxycontin: From Pain Relief to Drug Addiction,” The New York Times, Jul. 29, 2001, 14 pgs. |
| U.S. Pharmacopeia & National Formulary 24/19, The Standard of Quality, United States Pharmacopeial Convention, Inc., 1999, pp. 1233-1238, 1372-1375, 1941-1951, 2002-2003, 2442-2443, 2493-2498, National Publishing, Philadelphia, PA, United States. |
| U.S. Pharmacopeia, p. 2206, 1995. |
| Vicodin®, Physican Desk Reference, 1997, pp. 1404-1405, 51st Edition, Medical Economics Company, Inc., Montvale, United States. |
| Wilkins, Jeffrey, N., “Pharmacotherapy of Schizophrenia Patients with Comorbid Substance Abuse,” Schizophrenia Bulletin, vol. 23, No. 2, 1997, pp. 215-228. |
| Woodburn, K.R., et al., “Vascular Complications of Injecting Drug Misuse,” British Journal of Surgery, 1996, Vo. 83, p. 1329-1334. |
| Yang, et al., “Characterization of Compressibility and Compactibility of Poly(ethylene oxide) Polymers for Modified Release Application by Compaction Simulator,” Journal of Pharmaceutical Sciences, vol. 85, No. 10, Oct. 1996, pp. 1085-1090. |
| Zhang, Feng, Dissertation: “Hot-Melt Extrusion as a Novel Technology to Prepare Sustained-Release Dosage Forms,” The University of Texas at Austin, pp. v-xxv, 1-260, Dec. 1999, UMI Microform 9959618, Bell & Howell Information and Learning Company, Ann Arbor, MI, United States. |
| Zhang, F., et al., “Properties of Sustained-Release Tablets Prepared by Hot-Melt Extrusion,” Pharmaceutical Development and Technology, vol. 4, No. 2, pp. 241-250 (1999). |
| IPONZ, First Examination Report for Application No. 710782 dated Apr. 28, 2016. |
| CIPO, Office Action for Application No. 2,900,960 dated Jun. 16, 2016. |
| Extended European Search Report for Application No. 14765468.5 dated Jul. 26, 2016. |
| Number | Date | Country | |
|---|---|---|---|
| 20140271896 A1 | Sep 2014 | US |
| Number | Date | Country | |
|---|---|---|---|
| 61798213 | Mar 2013 | US |
